Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-1308A
MK-3475-02D
Phase 2 small_molecule active
Quick answer
Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-1308A for Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active